BELLUS Health Inc. (BLU) EPS Estimated At $-0.02; Wilbanks Smith & Thomas Asset Management Decreased Pfizer (PFE) Holding

Pfizer Inc. (NYSE:PFE) Logo

Analysts expect BELLUS Health Inc. (TSE:BLU) to report $-0.02 EPS on February, 20.They anticipate $0.01 EPS change or 33.33% from last quarter’s $-0.03 EPS. After having $-0.03 EPS previously, BELLUS Health Inc.’s analysts see -33.33% EPS growth. The stock increased 4.55% or $0.05 during the last trading session, reaching $1.15. About 51,579 shares traded. BELLUS Health Inc. (TSE:BLU) has 0.00% since February 14, 2018 and is . It has by 0.00% the S&P500.

Wilbanks Smith & Thomas Asset Management Llc decreased Pfizer Inc (PFE) stake by 9.25% reported in 2018Q3 SEC filing. Wilbanks Smith & Thomas Asset Management Llc sold 13,573 shares as Pfizer Inc (PFE)’s stock rose 5.56%. The Wilbanks Smith & Thomas Asset Management Llc holds 133,150 shares with $5.87M value, down from 146,723 last quarter. Pfizer Inc now has $241.05B valuation. The stock decreased 0.41% or $0.17 during the last trading session, reaching $41.7. About 23.49M shares traded. Pfizer Inc. (NYSE:PFE) has risen 25.07% since February 14, 2018 and is uptrending. It has outperformed by 25.07% the S&P500. Some Historical PFE News: 04/04/2018 – Pfizer: FDA Sets PDUFA Goal Date for Decision in September; 23/04/2018 – PFIZER RECEIVED A COMPLETE RESPONSE LETTER; 10/04/2018 – Novartis drug Afinitor DISPERZĀ® receives FDA approval to treat TSC-associated partial-onset seizures; 15/05/2018 – U.S. FDA – APPROVED RETACRIT AS BIOSIMILAR TO EPOGEN/PROCRIT FOR TREATMENT OF ANEMIA; 03/04/2018 – Jeffrey C. McCracken: Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price; 30/05/2018 – Pfizer’s Xeljanz Gets Expanded FDA Approval for Adults With Moderately to Severely Active Ulcerative Colitis; 10/04/2018 – PFIZER – INDEPENDENT COMMITTEE FOR PHASE 3 ATLAS TRIAL OF INLYTA RECOMMENDED STOPPING TRIAL AT A PLANNED INTERIM ANALYSIS DUE TO FUTILITY; 10/04/2018 – Pfizer to Move Its Headquarters to Hudson Yards Office Building; 07/05/2018 – FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer; 25/05/2018 – LUPIN LTD LUPN.NS SAYS CO ON COURSE WITH ITS PLANS FOR BIOSIMILAR ETANERCEPT FILING IN U.S. AND IS TARGETING THE SAME IN FY 2019-20

BELLUS Health Inc., a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need. The company has market cap of $180.60 million. The Company’s pipeline of projects include BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough; KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis, a rare fatal inflammatory condition that affects the lungs; and Shigamab for the treatment of hemolytic uremic syndrome caused by Shiga toxin-producing E. coli. It currently has negative earnings. The firm also has economic interests in various other partnered drug development projects, including AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.

More notable recent BELLUS Health Inc. (TSE:BLU) news were published by: which released: “The Alzheon IPO Will Fail – Seeking Alpha” on March 21, 2018, also with their article: “Netflix blows away competition with programming budget – Yahoo Finance” published on July 09, 2018, published: “CyberLink PowerDVD World’s First Software Player Certified for Ultra HD Blu-ray Disc Playback – Business Wire” on December 01, 2016. More interesting news about BELLUS Health Inc. (TSE:BLU) were released by: and their article: “Kryptowire Discovered Mobile Phone Firmware That Transmitted Personally Identifiable Information (PII) Without User Consent Or Disclosure – PR Newswire” published on November 15, 2016 as well as‘s news article titled: “5 Top Biotech and Pharma Stocks on the TSX Year-to-Date | INN – Investing News Network” with publication date: December 20, 2018.

Wilbanks Smith & Thomas Asset Management Llc increased Vanguard Index Fds (VO) stake by 3,800 shares to 48,960 valued at $8.04M in 2018Q3. It also upped Spdr Index Shs Fds (GWL) stake by 93,006 shares and now owns 415,400 shares. International Business Machs (NYSE:IBM) was raised too.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Pfizer Inc. (NYSE: PFE) and Astellas Announce Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer –” on February 11, 2019, also with their article: “Pfizer Biopharmaceuticals Group’s Late-Stage Pipeline Looks Well Positioned – Seeking Alpha” published on February 06, 2019, published: “Pfizer recalls contaminated high blood pressure drug in Japan – Seeking Alpha” on February 08, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Is Pfizer a Buy? – Motley Fool” published on January 16, 2019 as well as‘s news article titled: “EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC –” with publication date: February 11, 2019.

Investors sentiment increased to 0.85 in 2018 Q3. Its up 0.07, from 0.78 in 2018Q2. It improved, as 41 investors sold PFE shares while 741 reduced holdings. 142 funds opened positions while 520 raised stakes. 3.96 billion shares or 0.44% less from 3.98 billion shares in 2018Q2 were reported. Driehaus Cap Lc holds 0.01% of its portfolio in Pfizer Inc. (NYSE:PFE) for 8,194 shares. 806,804 are held by Sabal Tru. D L Carlson Gru Incorporated accumulated 0.14% or 11,421 shares. Federated Pa accumulated 5.69 million shares or 0.59% of the stock. Monarch has 119,613 shares for 1.91% of their portfolio. Paragon Cap Management Ltd Liability owns 7,000 shares. Of Vermont stated it has 275,287 shares. Mogy Joel R Investment Counsel stated it has 0.84% of its portfolio in Pfizer Inc. (NYSE:PFE). Altfest L J And Communications Incorporated reported 76,760 shares or 0.98% of all its holdings. Alpine Woods Investors holds 0.2% or 22,213 shares. Koshinski Asset Management stated it has 243,358 shares or 1.53% of all its holdings. Compton Cap Mgmt Ri accumulated 0.97% or 55,644 shares. Lynch Associates In holds 2.95% in Pfizer Inc. (NYSE:PFE) or 198,667 shares. Hays Advisory stated it has 0.2% in Pfizer Inc. (NYSE:PFE). Manchester Capital Mgmt Limited Liability holds 0.27% or 42,473 shares.

Since January 30, 2019, it had 0 insider buys, and 1 insider sale for $1.81 million activity. The insider LANKLER DOUGLAS M sold 43,800 shares worth $1.81 million.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart